MANEVeradermics, Inc.Finished
Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
Verruca Vulgaris · Warts · Common Wart
14Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Feb 2025, none posted yet
Counts until it's fixed
- +4
2 insiders sold shares within a month
Since Aug 19, 2026 · was worth 10, fading over time
Worry score14
Score over time
- Stage
- Phase 2
- Patients
- 153 (final count)
- Started
- Feb 28, 2023
- Main results expected
- Feb 25, 2025
- Fully finished
- Feb 25, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Proportion of subjects with complete clinical resolution of the Target Lesion at end of treatment period
Measured over: Baseline up to Day 134
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-02-25, no fading
- insider_selling_cluster: base 10, now 4, since 2026-08-19, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05799157 · record last updated 2025-05-08 · checked 2026-11-09 15:47 UTC